Home » Archive by Month

Article Archive for November 2009

FDA Decision scheduled for Santarus (SNTS)
11/23/2009 – 11:19 am PST | No Comment

Santarus, Inc. (NASDAQ:SNTS) expects the FDA to decide by December 4, 2009 regarding its NDA for ZEGERID tablet product. A NDA (New Drug Application) for DM-1796 is also expected to be filed with the FDA the …

CytRx Technical Breakout on Pending News (NASDAQ:CYTR)
11/23/2009 – 10:58 am PST | No Comment

Miv Investments Inc. has initiated an independent bullish technical trading alert for 11/23/09 on CytRx Corporation (NASDAQ:CYTR). Shares of the company finished trading during 11/20/09 at $1.14 per share.

Will the $20 million payment for VIBATIV pay off? (THRX, JNJ, ALPMF)
11/23/2009 – 7:10 am PST | No Comment

The FDA is anticipated to decide on 11/26/09 for Vibativ (telavancin) as a once-daily injectable antibiotic for the treatment of hospital-acquired pneumonia (HAP). This triggers a milestone payment of $10M from THRX’s partner, Astellas Pharma (ALPMF.PK). …

What You Need to Know about Home Equity Loans
11/23/2009 – 6:45 am PST | No Comment

Many home owners want to pull some equity out of their home (if they were lucky enough to buy before the real estate boom then bust) and use the proceeds to pay off debt or …

Echo Therapeutics Bullish on Recent News (OTC:ECTE)
11/20/2009 – 5:32 pm PST | No Comment

MivInvestments Inc. has initiated an independent bullish technical trading alert for 11/20/09 on Echo Therapeutics, Inc. (OTC:ECTE.OB). Shares of the company finished the day at $1.35, up 8.15% from the opening bell on heavy buying …

ImmunoGen’s Second License to Amgen (IMGN, AMGN)
11/20/2009 – 7:45 am PST | No Comment

ImmunoGen, Inc. (NASDAQ:IMGN) has announced that Amgen, Inc. (NASDAQ:AMGN)Inc has licensed the exclusive right to use ImmunoGen’s maytansinoid Targeted Antibody Payload (TAP) technology for the development of anticancer therapeutics to an undisclosed target.

CombinatoRx & Neuromed Merger at risk? (NASDAQ:CRXX)
11/20/2009 – 7:30 am PST | One Comment

Neuromed and CombinatoRx, Incorporated (NASDAQ:CRXX)has agreed to sign a definitive merger agreement valued $28.8 million USD on 30th June, 2009 according to a news published by the RTT News.

Sucampo Granted Marketing Authorization From FDA (NASDAQ:SCMP)
11/20/2009 – 6:50 am PST | No Comment

Sucampo Pharma Europe Ltd, a subsidiary of Sucampo Pharmaceuticals Inc (NASDAQ:SCMP) has announced that Swissmedic has granted a marketing authorization for Amitiza 24 mcg gel capsules for the long term treatment of patients with chronic …